Titre :
  • A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Auteur : Dumez, Herlinde ; Awada, Ahmad ; Piccart-Gebhart, Martine ; Assadourian, S ; Semiond, D ; Guetens, G ; De Boeck, Geneviève ; Maes, R A A ; de Bruijn, E A ; van Oosterom, A
Informations sur la publication : Annals of oncology, 17, 7, (page 1158-1165)
Statut de publication : Publié, 2006-07
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés : CPT-11
Dose-escalation
Dose-limiting toxicity
Irinotecan
Oral
Powder-filled capsule
Mots-clés MeSH : Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- adverse effects
Antineoplastic Agents, Phytogenic -- pharmacokinetics
Area Under Curve
Camptothecin -- administration & dosage
Camptothecin -- analogs & derivatives
Camptothecin -- pharmacokinetics
Camptothecin -- toxicity
DNA Topoisomerases, Type I -- antagonists & inhibitors
Female
Humans
Male
Middle Aged
Neoplasms -- drug therapy
Note : Clinical Trial, Phase I
Journal Article
Langue :
  • Anglais
Identificateurs : urn:issn:0923-7534 
info:doi/10.1093/annonc/mdl071
info:pii/mdl071
info:pmid/16600980